Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Greece has been experiencing significant growth in recent years.
Customer preferences: Greek customers have shown a growing demand for innovative oncology drugs. They are willing to pay a premium for drugs that are effective and have minimal side effects. Patients also prefer drugs that require less frequent dosing and have a shorter treatment duration. This preference for convenience and efficacy has driven the growth of targeted therapies and immunotherapies in the Greek market.
Trends in the market: The Greek Oncology Drugs market has been growing at a steady pace due to the increasing prevalence of cancer in the country. The market is also benefiting from the development of new drugs, particularly targeted therapies and immunotherapies. These drugs have shown promising results in clinical trials, leading to their approval by regulatory authorities and subsequent adoption by healthcare providers. The trend towards personalized medicine has also contributed to the growth of the market, as patients are increasingly being treated with drugs that are tailored to their specific genetic profile.
Local special circumstances: The Greek healthcare system has been under significant pressure in recent years due to the economic crisis. This has led to a reduction in healthcare spending and a decrease in the number of hospital beds and healthcare professionals. However, the government has recently taken steps to improve the healthcare system, including increasing funding for cancer treatment and prevention. This has had a positive impact on the Oncology Drugs market, as patients are now able to access more advanced treatments.
Underlying macroeconomic factors: The Greek economy has been slowly recovering from the economic crisis, with GDP growth averaging around 2% in recent years. The government has also implemented a number of reforms aimed at improving the business environment and attracting foreign investment. These factors have contributed to the growth of the Oncology Drugs market, as pharmaceutical companies are now more willing to invest in the Greek market. However, the market still faces challenges, including the high cost of drugs and the limited resources of the healthcare system.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
